Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated PMRT with a positive deep margin?
How would you dose?
Answer from: Radiation Oncologist at Community Practice
I have used hypofractionated RT in this setting with final boost to area of positive margin equivalent to 60 Gy
Comments
Radiation Oncologist at Charlotte Hungerford Hospital
Thank you!
Radiation Oncologist at Bismarck Cancer Center
I agree, with a caveat - if the pathology report d...
Radiation Oncologist at Mallory Radiotherapy, PLLC
Dr. @Beriwal, what bolus regimen for the primary a...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
If it’s a deep margin, then may avoid bolus ...
1396
1399
13525
13535
Sign in or Register to read more
5215
Related Questions
Is DCISionRT appropriate for multifocal DCIS?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
When treating chestwall + RNI with VMAT, how much do you crop the PTV into lung as is done with the PTVeval in 3D contouring guides?
Do you recommend re-excision of a unifocal positive anterior margin at skin after lumpectomy in a patient with otherwise low risk breast cancer features?
Would you omit radiation for an elderly woman with bilateral breast cancers (both early-stage disease and ER+/PR+/HER2 negative) who otherwise meets the criteria for endocrine therapy alone?
How would you treat a young breast cancer patient with limited nodal involvement and an isolated sternal oligometastasis at diagnosis?
Under what circumstances would you offer PMRT in a patient with DCIS?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
Thank you!
I agree, with a caveat - if the pathology report d...
Dr. @Beriwal, what bolus regimen for the primary a...
If it’s a deep margin, then may avoid bolus ...